Persisting bone marrow aplasia following interferon-alpha combined with ara-C for chronic myelogenous leukemia

Leukemia and Lymphoma

Volumn 34, Issue 1-2, 1999, Pages 191-195

  Fiegl, M ^a   Chott, A ^b   Seewann, H L ^b   Lechner, K ^b   Gisslinger, H ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Ara C; Bone marrow aplasia; CML; Cytarabine; Hydroxyurea; IFN; Interferon

Indexed keywords

ALPHA2 INTERFERON; CYTARABINE; HYDROXYUREA;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLOOD TOXICITY; BONE MARROW APLASIA; BONE MARROW EXAMINATION; CANCER REGRESSION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; HEMATOPOIESIS; HUMAN; HUMAN CELL; MAINTENANCE THERAPY; MALE; METAPHASE; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PANCYTOPENIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0033035793     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909083397     Document Type: Article

References (15)

1. Guilhot F., Chastang C., Michallet M., Guerci A., Harousseau J.L., Maloisel F., Bouabdallah R., Guyotat D., Cheron N., Nicolini F., Abgrall J. F., Tanzer J. (1997). Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. New England Journal of Medicine, 337, 223-229.
2. Kantarjian H. M., Keating M. J., Estey E. H., O'Brien S, Pierce S., Beran M., Koller C., Feldman E., Talpaz M. (1992). Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. Journal of Clinical Oncololgy, 10, 772-778.
3. Ferrajoli A., Liberati A. M., Caricchi P., Donti E., Morra E., Lazzarino M., Betti A. R., Bernasconi P., Saglio G. (1995). Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patients. European Journal of Haematology, 55, 184-188.
4. Thaler J., Hilbe W., Apfelbeck U., Linkesch W., Sill H., Seewann H., Pont J., Bernhart M., Stoger M., Niessner H., Abbrederis K., Geissler D., Hausmaninger H., Lin W., Ludwig H., Lang A., Duba C., Fluckinger T., Greil R., Grunewald K., Konwalinka G., Niederwieser D., Fridrik M. (1997). Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II study. Leukemia Research, 21, 75-80.
5. Foss F. M., Ihde D. C., Linnoila I. R., Fischmann A. B., Schechter G. P., Cotelingam J. D., Steinberg S. M., Ghosh B. C., Stocker J. L., Bastian A., Phares J. C., Sausville E. A. (1994). Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. Journal of Clinical Oncology, 12, 2051-2059.
6. Hoffmann A., Kirn F., Krueger G. R. F., Fischer R. (1994). Bone marrow hypoplasia and fibrosis following interferon treatment. In vivo, 8, 605-612.
7. Talpaz M., Kantarjian H., Kurzrock R., Gutterman J. U. (1992). Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia. Cancer, 69, 410-412.
8. Shepherd P. C. A., Richards S., Allan N. C. (1994). Severe cytopenias associated with the sequential use of busulphan and interferon-alpha in chronic myeloid leukaemia. British Journal of Haematology, 86, 92-96.
9. Fattovich G., Giustina G., Favarato S., Ruol A. (1996). A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. Journal of Hepatology, 24, 38-47.
10. Maciejewski J. P., Selleri C., Sato T., Anderson S., Young N. S. (1995). Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anemia. British Journal of Hematology, 91, 245-252.
11. Zoumbos N. C. , Gascon P., Djeu J. Y., Young N. S. (1985). Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proceedings of the National Academy of Sciences USA, 82, 188-192.
12. Binder D., van den Broek M. F., Kagi D., Bluethmann H., Fehr J., Hengartner H., Zinkemagel R. M. (1998). Aplastic anemia rescued by exhaustion of cytokine-secreting VD8+ T cells in persistent infection with lymphocytic choriomeningitis virus. Journal of Experimental Medicine, 187, 1903-1920.
13. Kimura Y., Kajiyama K., Nomura H., Shiraishi G. (1994). Severe thrombocytopenia during interferon-alpha therapy for chronic active hepatitis C associated with systemic lupus erythematosus. Fukuoka Igaku Zasshi, 85, 329-333.
14. Siciliano R., Trovato B. A., Seminara G., Giustolisi V., Malaguarnera M. (1995). Interferon or hepatitis C virus induced autoimmune aplastic anemia and severe thrombocytopenia? A case report. Ann Ital Med Int., 10, 193-194.
15. Mangan K. F., Zidar B., Shadduck R. K., Zeigler Z., Winkelstein A. (1985). Interferon-induced aplasia: evidence for T-cell-mediated suppression of hematopoiesis and recovery after treatment with horse antihuman thymocyte globulin. American Journal of Hematology, 19, 401-413.